Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) trades at $1.46 with AI Score 45/100 (Grade C). Shanghai Pharmaceuticals Holding Co. , Ltd. Market cap: $8.46B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for SHPMF: SHPMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SHPMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SHPMF: the 1 perspectives are evenly split.
How is this calculated? →Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Healthcare & Pipeline Overview
Shanghai Pharmaceuticals Holding Co., Ltd. is a major player in the Chinese pharmaceutical market, with a diversified portfolio spanning drug manufacturing, distribution, and retail. The company's extensive network of retail pharmacies and focus on key therapeutic areas position it competitively within China's growing healthcare sector, supported by a beta of 0.33.
What Is the Investment Thesis for SHPMF?
Shanghai Pharmaceuticals presents a compelling investment case based on its established market position and diversified operations within China's expanding healthcare sector. With a P/E ratio of 10.4 and a dividend yield of 2.37%, the company offers a blend of value and income. Growth catalysts include the increasing demand for healthcare products and services in China, driven by an aging population and rising income levels. The company's extensive distribution network and retail presence provide a competitive edge. However, investors may want to evaluate the risks associated with regulatory changes in the pharmaceutical industry and the competitive pressures from both domestic and international players. The company's profit margin of 2.0% and gross margin of 10.6% indicate areas for potential improvement in operational efficiency.
Based on FMP financials and quantitative analysis
SHPMF Key Highlights
- Market capitalization of $8.46B, reflecting its significant presence in the Chinese pharmaceutical market.
- P/E ratio of 10.4, suggesting a potentially undervalued investment relative to its earnings.
- Dividend yield of 2.37%, offering a steady income stream for investors.
- Gross margin of 10.6%, indicating the profitability of its core business activities.
- Beta of 0.33, suggesting lower volatility compared to the overall market.
Who Are SHPMF's Competitors?
SHPMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDUUF Bangkok Dusit Medical Services Public Company Limited | $0.60 | -6.25% | $9.54B | 52 |
| ESAIY Eisai Co., Ltd. | $6.66 | +2.78% | $7.52B | 55 |
| ESALF Eisai Co., Ltd. | $25.00 | +0.00% | $7.05B | 61 |
| GIFOF Grifols, S.A. | $8.85 | +0.00% | $8.70B | 52 |
| KYKOF Kyowa Kirin Co., Ltd. | $14.20 | -1.56% | $7.43B | 57 |
| CWB State Street SPDR Bloomberg Convertible Securities ETF | $105.34 | +0.92% | $4.62B | 47 |
| TDV ProShares - S&P Technology Dividend Aristocrats ETF | $100.89 | +1.33% | $293.21M | 47 |
| DAUG FT Vest U.S. Equity Deep Buffer ETF - August | $46.97 | +0.26% | $363.40M | 47 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SHPMF's Key Strengths?
- Extensive distribution network and retail presence in China.
- Diversified product portfolio spanning various therapeutic areas.
- Strong brand recognition and reputation.
- Established relationships with hospitals and healthcare providers.
What Are SHPMF's Weaknesses?
- Relatively low profit margin compared to global peers.
- Dependence on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited presence in international markets.
What Could Drive SHPMF Stock Higher?
- Expansion of the online pharmacy business to capture a larger market share.
- Increased investment in R&D to develop innovative drugs and expand the product portfolio.
- Potential strategic partnerships and acquisitions to expand market reach and access new technologies.
- Development of value-added services to generate additional revenue streams and enhance customer loyalty.
- Government policies supporting the growth of the pharmaceutical industry in China.
What Are the Key Risks for SHPMF?
- Increasing competition from domestic and international players in the Chinese pharmaceutical market.
- Pricing pressures from generic drugs and government regulations.
- Regulatory changes and compliance requirements that could impact operations and profitability.
- Economic slowdown in China that could reduce demand for pharmaceutical products.
- Risks associated with operating in the OTC market, including limited liquidity and disclosure.
What Are the Growth Opportunities for SHPMF?
- Expansion of Online Pharmacy Business: Shanghai Pharmaceuticals can capitalize on the growing trend of online pharmacies in China. By expanding its online platform and offering a wider range of products and services, the company can reach a larger customer base and increase its market share. The e-commerce market in China is expected to continue its double-digit growth, providing a significant opportunity for the company. Timeline: Ongoing.
- Increased Focus on R&D and Innovative Drugs: Investing in research and development to develop innovative drugs can drive future growth. The company can focus on developing drugs for therapeutic areas with unmet needs, such as oncology and CNS disorders. This will not only enhance its product portfolio but also improve its profitability. The Chinese government is also encouraging innovation in the pharmaceutical industry, providing further support for R&D activities. Timeline: Ongoing.
- Expansion into Rural Markets: Expanding its retail pharmacy network into rural areas can provide access to a large untapped market. The healthcare needs in rural areas are often underserved, presenting a significant opportunity for growth. The company can leverage its existing distribution network to efficiently serve these markets. Timeline: Upcoming, within 2-3 years.
- Strategic Partnerships and Acquisitions: Forming strategic partnerships with other pharmaceutical companies or acquiring smaller players can help expand its product portfolio and market reach. This can also provide access to new technologies and expertise. The pharmaceutical industry is consolidating globally, and Shanghai Pharmaceuticals can benefit from this trend. Timeline: Ongoing.
- Development of Value-Added Services: The company can further develop its value-added services, such as consulting, asset management, clinical trials, medical aid, and physician and patient education. These services can generate additional revenue streams and enhance customer loyalty. The demand for these services is increasing as healthcare becomes more complex and patients become more informed. Timeline: Ongoing.
What Opportunities Does SHPMF Have?
- Expansion into rural markets in China.
- Increased focus on R&D and innovative drugs.
- Strategic partnerships and acquisitions.
- Development of value-added services.
What Threats Does SHPMF Face?
- Increasing competition from domestic and international players.
- Pricing pressures from generic drugs.
- Regulatory changes and compliance requirements.
- Economic slowdown in China.
What Are SHPMF's Competitive Advantages?
- Extensive distribution network and retail presence in China.
- Diversified product portfolio spanning various therapeutic areas.
- Strong brand recognition and reputation in the Chinese pharmaceutical market.
- Established relationships with hospitals and healthcare providers.
What Does SHPMF Do?
Founded in 1994 and headquartered in Shanghai, Shanghai Pharmaceuticals Holding Co., Ltd. has evolved into a comprehensive pharmaceutical enterprise. As an investment holding company and a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., it is deeply rooted in the Chinese healthcare landscape. The company operates through four key segments: Production, Distribution, Retail, and Others. Its product offerings encompass a wide array of pharmaceuticals, including chemicals and biochemicals, traditional Chinese medicines, healthcare products, and medical devices. These products target various therapeutic areas such as oncology, cerebrocardiovascular diseases, central nervous system disorders, general infections, immunology, digestive and metabolic ailments, and respiratory conditions. Shanghai Pharmaceuticals provides approximately 700 drug varieties. Beyond manufacturing, the company offers extensive pharmaceutical distribution, warehousing, and logistics services. It also manages a network of approximately 2,000 retail chain pharmacies across 24 provinces, complemented by an online drug business. The company extends its services to consulting, asset management, clinical trials, medical aid, and physician and patient education, further solidifying its presence in the healthcare ecosystem.
What Products and Services Does SHPMF Offer?
- Researches and develops pharmaceutical products.
- Manufactures a wide range of drugs, including chemicals, biochemicals, and traditional Chinese medicines.
- Distributes pharmaceutical products to hospitals, distributors, and retail pharmacies.
- Operates a network of approximately 2,000 retail chain pharmacies.
- Provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions.
- Engages in online drug business.
- Offers consulting services, asset management operations, and clinical trials.
- Provides medical aid, physicians and patients' education, e-prescription management, and remote and cloud hospitals.
How Does SHPMF Make Money?
- Manufacturing and selling pharmaceutical products.
- Providing pharmaceutical distribution and logistics services.
- Operating retail pharmacies and selling drugs directly to consumers.
- Offering value-added services such as consulting and clinical trials.
What Industry Does SHPMF Operate In?
Shanghai Pharmaceuticals operates within the rapidly growing Chinese pharmaceutical market. The industry is characterized by increasing demand for healthcare products and services, driven by an aging population, rising income levels, and increasing health awareness. The company faces competition from both domestic players and international pharmaceutical giants. Key trends include the increasing adoption of generic drugs, the growing importance of online pharmacies, and the evolving regulatory landscape. The company's extensive distribution network and retail presence provide a competitive advantage in this dynamic market.
Who Are SHPMF's Key Customers?
- Hospitals and healthcare providers.
- Pharmaceutical distributors.
- Retail pharmacies.
- Individual consumers.
FY2026 estForward Outlook
Wall Street analysts project Shanghai Pharmaceuticals Holding Co., Ltd revenue of about $296.97B for fiscal 2026, with EPS near $1.41. The estimate reflects 9 contributing analysts.
F-Score 6/9Financial Health
Shanghai Pharmaceuticals Holding Co., Ltd's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.05 places it in the grey zone, a middle ground that warrants monitoring.
ROE 8%Key Financial Metrics
Return on equity for Shanghai Pharmaceuticals Holding Co., Ltd stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. SHPMF trades at a trailing price-to-earnings ratio of 10.37, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 9.8%, the inverse of the P/E and a quick read on earnings relative to price.
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) Valuation Context
Valued at $8.46B, SHPMF is classified as a mid-cap stock. Relative to its peer group, SHPMF's quantitative score of 45/100 is below the peer average of 55/100.
Company Profile
Shanghai Pharmaceuticals Holding Co., Ltd operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Qiuhua Yang. SHPMF has traded publicly since 2013.
SHPMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Extensive distribution network and retail presence in China.
- Diversified product portfolio spanning various therapeutic areas.
- Strong brand recognition and reputation.
- Established relationships with hospitals and healthcare providers.
Bear Case
- Relatively low profit margin compared to global peers.
- Dependence on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited presence in international markets.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
SHPMF Latest News
No recent news available for SHPMF.
SHPMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SHPMF.
Price Targets
Wall Street price target analysis for SHPMF.
SHPMF MoonshotScore
What does this score mean?
The MoonshotScore rates SHPMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Qiuhua Yang
CEO
Qiuhua Yang is the CEO of Shanghai Pharmaceuticals Holding Co., Ltd. Details regarding Yang's specific educational background and prior roles are not available in the provided data. As the CEO, Yang is responsible for leading the company's strategic direction, overseeing its operations, and managing its relationships with stakeholders. Yang's leadership is crucial for navigating the complex regulatory environment and competitive landscape of the Chinese pharmaceutical market.
Track Record: As CEO of Shanghai Pharmaceuticals, Qiuhua Yang manages a large workforce of 49,402 employees. Specific achievements and strategic decisions under Yang's leadership are not detailed in the provided data. However, the company's continued growth and expansion in the Chinese pharmaceutical market reflect Yang's ability to guide the company effectively. Further information is needed to fully assess Yang's track record.
SHPMF OTC Market Information
The OTC Other tier, where SHPMF trades, represents the lowest tier of the OTC market. Companies in this tier may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. This often indicates limited financial disclosure and potentially higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should be aware that companies in this tier may have limited operating history or be in early stages of development.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and the risk of fraud.
- Low liquidity can make it difficult to exit the investment.
- Lack of regulatory oversight compared to major exchanges.
- Potential for price manipulation due to low trading volume.
- Higher risk of company failure or delisting.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the company's regulatory environment and compliance requirements.
- Evaluate the company's liquidity and trading volume.
- Consult with a financial advisor before investing.
- Subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
- Operates a large network of retail pharmacies.
- Involved in the research, development, and manufacturing of pharmaceutical products.
- Presence in the Chinese pharmaceutical market since 1994.
SHPMF Healthcare Stock FAQ
What does Shanghai Pharmaceuticals Holding Co., Ltd do?
Shanghai Pharmaceuticals Holding Co., Ltd. is a comprehensive pharmaceutical company operating across the value chain, from research and development to manufacturing, distribution, and retail. The company produces a wide range of pharmaceutical products, including chemicals, biochemicals, and traditional Chinese medicines, targeting various therapeutic areas. Its extensive distribution network and retail pharmacy chain provide a strong market presence in China, complemented by online drug sales and value-added services like consulting and clinical trials.
What are the main risks for SHPMF?
The main risks for Shanghai Pharmaceuticals include increasing competition in the Chinese pharmaceutical market, pricing pressures from generic drugs, and regulatory changes that could impact operations. As an OTC-listed company, SHPMF also faces risks associated with limited liquidity and disclosure. Investors should carefully consider these factors and conduct thorough due diligence before investing.
What are the key factors to evaluate for SHPMF?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) holds an AI score of 45/100 (low). P/E: 10.4x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does SHPMF data refresh on this page?
SHPMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SHPMF's recent stock price performance?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive distribution network and retail presence in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SHPMF overvalued or undervalued right now?
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF) trades at 10.4x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SHPMF?
Before investing in Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SHPMF to a portfolio?
Key strength of Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF): Extensive distribution network and retail presence in China. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide further insights.